Gain Therapeutics Net Income
| GANX Stock | USD 1.81 0.08 4.62% |
As of the 16th of February 2026, Gain Therapeutics retains the Standard Deviation of 8.64, market risk adjusted performance of (0.12), and Risk Adjusted Performance of 0.0038. Gain Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Gain Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 138.3348 | Earnings Share (0.61) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -18.4 M | -19.3 M | |
| Net Loss | -15.8 M | -15 M | |
| Net Loss | -18.4 M | -19.3 M | |
| Net Loss | (1.03) | (1.08) | |
| Net Income Per E B T | 0.92 | 0.81 |
Gain | Net Income | Build AI portfolio with Gain Stock |
The evolution of Net Income for Gain Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Gain Therapeutics compares to historical norms and industry peers.
Latest Gain Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Gain Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Gain Therapeutics financial statement analysis. It represents the amount of money remaining after all of Gain Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Gain Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (20.41 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Gain Net Income Regression Statistics
| Arithmetic Mean | (7,502,335) | |
| Coefficient Of Variation | (115.25) | |
| Mean Deviation | 7,859,376 | |
| Median | (1,105,540) | |
| Standard Deviation | 8,646,229 | |
| Sample Variance | 74.8T | |
| Range | 21.2M | |
| R-Value | (0.86) | |
| Mean Square Error | 21.3T | |
| R-Squared | 0.73 | |
| Significance | 0.000011 | |
| Slope | (1,466,392) | |
| Total Sum of Squares | 1196.1T |
Gain Net Income History
Other Fundumenentals of Gain Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Gain Therapeutics Net Income component correlations
Gain Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Gain Therapeutics is extremely important. It helps to project a fair market value of Gain Stock properly, considering its historical fundamentals such as Net Income. Since Gain Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gain Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gain Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. Market participants price Gain higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Gain Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Gain Therapeutics requires distinguishing between market price and book value, where the latter reflects Gain's accounting equity. The concept of intrinsic value - what Gain Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Gain Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Gain Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Gain Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Gain Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Gain Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Gain Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Gain Therapeutics or generate 0.0% return on investment in Gain Therapeutics over 90 days. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by pr... More
Gain Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Gain Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Gain Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 55.91 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 10.07 |
Gain Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gain Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Gain Therapeutics' standard deviation. In reality, there are many statistical measures that can use Gain Therapeutics historical prices to predict the future Gain Therapeutics' volatility.| Risk Adjusted Performance | 0.0038 | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.71) | |||
| Treynor Ratio | (0.13) |
Gain Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0038 | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 5.59 | |||
| Coefficient Of Variation | (15,335) | |||
| Standard Deviation | 8.64 | |||
| Variance | 74.69 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.71) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 55.91 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 10.07 | |||
| Skewness | (1.60) | |||
| Kurtosis | 11.05 |
Gain Therapeutics Backtested Returns
Gain Therapeutics holds Efficiency (Sharpe) Ratio of -0.0337, which attests that the entity had a -0.0337 % return per unit of risk over the last 3 months. Gain Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Gain Therapeutics' Standard Deviation of 8.64, market risk adjusted performance of (0.12), and Risk Adjusted Performance of 0.0038 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Gain Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Gain Therapeutics is expected to be smaller as well. At this point, Gain Therapeutics has a negative expected return of -0.3%. Please make sure to check out Gain Therapeutics' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Gain Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.29 |
Weak reverse predictability
Gain Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Gain Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Gain Therapeutics price movement. The serial correlation of -0.29 indicates that nearly 29.0% of current Gain Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.29 | |
| Spearman Rank Test | -0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Gain Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Gain Therapeutics reported net income of (20.41 Million). This is 105.98% lower than that of the Biotechnology sector and 129.14% lower than that of the Health Care industry. The net income for all United States stocks is 103.57% higher than that of the company.
Gain Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gain Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gain Therapeutics could also be used in its relative valuation, which is a method of valuing Gain Therapeutics by comparing valuation metrics of similar companies.Gain Therapeutics is currently under evaluation in net income category among its peers.
Gain Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Gain Therapeutics from analyzing Gain Therapeutics' financial statements. These drivers represent accounts that assess Gain Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Gain Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 55.2M | 37.2M | 42.5M | 49.4M | 56.8M | 74.9M | |
| Enterprise Value | 19.9M | 31.2M | 31.8M | 39.7M | 45.6M | 64.4M |
Gain Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Gain Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Gain Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gain Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 76.5 K | State Street Corp | 2025-06-30 | 71.1 K | Kovitz Investment Group Partners, Llc | 2025-06-30 | 47.6 K | Dauntless Investment Group, Llc | 2025-06-30 | 46 K | Springbok Capital Management, Llc | 2025-06-30 | 35.8 K | Ubs Group Ag | 2025-06-30 | 32.6 K | Bridgeway Capital Management, Llc | 2025-06-30 | 30 K | Virtu Financial Llc | 2025-06-30 | 23.8 K | Benedict Financial Advisors, Inc. | 2025-06-30 | 22.5 K | Jones Financial Companies Lllp | 2025-06-30 | 676.9 K | Vanguard Group Inc | 2025-06-30 | 534.4 K |
Gain Fundamentals
| Return On Equity | -2.62 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 61.07 M | ||||
| Shares Outstanding | 38.46 M | ||||
| Shares Owned By Insiders | 3.39 % | ||||
| Shares Owned By Institutions | 20.14 % | ||||
| Number Of Shares Shorted | 2.98 M | ||||
| Price To Book | 11.72 X | ||||
| Price To Sales | 255.50 X | ||||
| Gross Profit | (8.95 M) | ||||
| EBITDA | (20.27 M) | ||||
| Net Income | (20.41 M) | ||||
| Cash And Equivalents | 24.25 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 653.01 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (18.87 M) | ||||
| Short Ratio | 2.81 X | ||||
| Earnings Per Share | (0.61) X | ||||
| Target Price | 7.6 | ||||
| Number Of Employees | 23 | ||||
| Beta | 0.057 | ||||
| Market Capitalization | 69.62 M | ||||
| Total Asset | 12.12 M | ||||
| Retained Earnings | (81.19 M) | ||||
| Working Capital | 7.69 M | ||||
| Net Asset | 12.12 M |
About Gain Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gain Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.